Two courses in Late Phase and Outcomes Research
MSc, Health Care and Epidemiology, University of British Columbia, 2008
Dissertation “Effectiveness of inhaled corticosteroids in preventing morbidity and mortality in individuals with chronic
obstructive pulmonary disease and the impact of coexisting asthma”
BSc, Mathematics (biology minor), University of Victoria, 2002
At Oxford Outcomes
Sarah is a director of epidemiology at Oxford Outcomes. She has designed, managed, and conducted systematic review
studies in a wide range of disease areas, and has extensive experience in incorporating evidence synthesis techniques
including network meta-analysis. She has conducted systematic reviews of randomized and non-randomized studies, with
qualitative and quantitative evidence synthesis on a variety of outcome scales.
Sarah also has experience in managing and conducting a wide range of additional pharmacoepidemiological study
types across the drug development lifecycle. These include burden of illness studies, drug utilization studies and health
economic modelling in a variety of disease areas, such as: diabetes (type 1 and type 2), hepatitis C, renal disease,
Alzheimer’s disease, asthma, chronic obstructive pulmonary disease, nosocomial infections, and heart disease.
Sarah’s experience in economic modelling includes implementing de novo health economic models as well as designing
and conducting epidemiological studies – including network meta-analysis studies – to populate model parameters.
She has prepared submissions to HTA bodies in the UK and Canada, for clinical effectiveness and cost-effectiveness
components of submission dossiers.
Sarah’s methodological interests include technical aspects of evidence synthesis, including critical evaluation of trial
characteristics for informing the design and analysis of treatment networks.
Publications and conference proceedings
Goring S, Huang T, Wygant G, et al. Efficacy of dapagliflozin compared with other oral antidiabetic agents added to
metformin monotherapy among subjects with type 2 diabetes . 48th Annual Meeting of the European Association for
the study of Diabetes. Berlin, Germany, Oct 2012. (Abstract)
Goring SM, Ghement I, Kalsekar A, L’Italien G, Levy A. Impact of the choice of prior distribution on relative effect sizes
using Bayesian network meta-analysis. International Society for Pharmacoeconomics and Outcomes Research 14th
Annual European Congress. Madrid, Spain, Novemeber 2011. (Podium presentation)
Two courses in Late Phase and Outcomes Research
Goring SM, L. Cochrane, P. Donnan, A. Bell, D. Heather, S. Lane, A. Levy, S. Greene. The clinical and economic burden of type 1 diabetes in children, adolescents and adults. 47th Annual Meeting of the European Association for the Study of Diabetes. Lisbon, Portugal, Sept 2011. (Abstract)Smith DM, Johnson ES, Weiss J, Petrik A, Yang X, Goring S, Lane S, Thorp M, Levy A. The Economic Burden of Illness of Type I Diabetes in a Health Maintenance Organization (HMO) Setting in the United States. American Diabetes Association. San Diego, June 2011. (Abstract)Goring SM, Eyawo O, Mills EJ, Levy AR, L’Italien G, Trivedi D, Kasiske B. A Mixed Treatment Comparison of Efficacy and Cardiometabolic Safety of Belatacept, Cyclosporine and Tacrolimus for Immunosuppression Therapy in Adult Renal Transplant Recipients. XXIII International Congress of the Transplantation Society. Vancouver, August 2010. (Abstract)Goring SM, Mills EJ, Skovron ML, Corey-Lisle PK, Levy AR. A Systematic Literature Review of Post-Transplant Lymphoproliferative Disorder in Randomized Trials of Agents for the Prevention of Allograft Rejection in Renal Transplant. American Transplant Congress. San Diego, May 2010. (Abstract)Davie AM, Brazier N, Tsao N, Goring SM, Albrecht LE, Gratton D, Lynde CW, Jivraj F, Levy AR. Economic Burden Of Moderate To Severe Chronic Plaque Psoriasis In Canada. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th international meeting. Orlando, May 2009. (Abstract)Goring SM, Levy AR, Carleton B, Briggs A, Levy RD. Effectiveness of Inhaled Corticosteroids in Preventing Morbidity and Mortality in Individuals with Chronic Obstructive Pulmonary Disease and the Impact of Coexisting Asthma. American Thoracic Society International Conference. San Diego, May 2009. (Abstract)Goring SM, Levy RD, Camp P, Briggs A, Carleton B, Levy AR. Estimating the Direct Medical Costs of Treating COPD in British Columbia (BC), Canada, Using Discrete Event Simulation. American Thoracic Society International Conference. San Francisco, May 2007. (Abstract)
Assessing the impact of Cry1Ab-expressing corn pollen on monarch butterfly larvae in field studies Diane E. Stanley-Horn*†, Galen P. Dively‡, Richard L. Hellmich§, Heather R. Mattila*, Mark K. Sears*, Robyn Rose‡, Laura C. H. Jesse¶, John E. Losey ʈ , John J. Obrycki¶, and Les Lewis§ *Department of Environmental Biology, University of Guelph, Guelph, ON, Canada N1G 2W1; ‡Depa
Cooley Alert ! News from our Government Contracts Group The Significant Risk to SBIR Program Participants Under the False Claims Act based on incorrect statements of fact, and as the basis for his qui tam action. After nies, the U.S. Government’s Small Business a lengthy investigation, the United States Innovation Research (“SBIR”) Program is ment for performance of that co